Tissue Regenix Group PLC CEO to return to full time duties (6208Z)

TIDMTRX

RNS Number : 6208Z

Tissue Regenix Group PLC

21 May 2019

Tissue Regenix Group plc

Chief Executive Officer to return to full time duties

Leeds, 21 May 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that Steve Couldwell, Chief Executive Officer (CEO), will return to full time duties during June.

John Samuel, Chairman, Tissue Regenix Group plc: "The Board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment. During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establishing future business developments, along with the support of Gareth Jones who undertook the Chief Operating Officer role during this period. The business has continued to develop in line with the Board expectations."

For more Information:

 
 Tissue Regenix Group plc                       Tel: [phone] / 
  Caitlin Pearson Head of Communications         07920272 441 
---------------------------------------------  --------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated      Tel: [phone] 
  Adviser and Broker) 
  Jonathan Senior / Alex Price / Ben Maddison 
---------------------------------------------  --------------------- 
 
 FTI Consulting                                 Tel: [phone] 
  Brett Pollard / Victoria Foster Mitchell 
  / Mary Whittow 
=============================================  ===================== 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOADBLFLKEFXBBD

(END) Dow Jones Newswires

May 21, 2019 02:02 ET (06:02 GMT)